Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanxin Lu

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Vaccine|August 31, 2015
Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigsGregory M Glenn, Louis F Fries, Gale Smith, et al.
Vaccine|November 4, 2018
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challengeBrian E Gilbert, Nita Patel, Hanxin Lu, et al.
Vaccine|October 1, 2014
An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunizationRama Raghunandan, Hanxin Lu, Bin Zhou, et al.
Plos One|December 11, 2012
Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton ratsGale Smith, Rama Raghunandan, Yingyun Wu, et al.
Molecular and Cellular Biology|June 8, 2002
Acetylation of nucleosomal histones by p300 facilitates transcription from tax-responsive human T-cell leukemia virus type 1 chromatin templateHanxin Lu, Cynthia A Pise-Masison, Terace M Fletcher, et al.
Immunity & Ageing : I & A|April 18, 2017
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adultsLouis Fries, Vivek Shinde, Jeffrey J Stoddard, et al.
Vaccine|June 6, 2017
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing ageAllison August, Gregory M Glenn, Eloi Kpamegan, et al.
The Journal of Infectious Diseases|August 12, 2015
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing AgeGregory M Glenn, Louis F Fries, D Nigel Thomas, et al.
Vaccine|August 17, 2019
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protectionNita Patel, Mike J Massare, Jing-Hui Tian, et al.
Vaccine|November 17, 2012
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccineGregory M Glenn, Gale Smith, Louis Fries, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Vaccine|August 31, 2015
Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigsGregory M Glenn, Louis F Fries, Gale Smith, et al.
Vaccine|November 4, 2018
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challengeBrian E Gilbert, Nita Patel, Hanxin Lu, et al.
Vaccine|October 1, 2014
An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunizationRama Raghunandan, Hanxin Lu, Bin Zhou, et al.
Plos One|December 11, 2012
Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton ratsGale Smith, Rama Raghunandan, Yingyun Wu, et al.
Molecular and Cellular Biology|June 8, 2002
Acetylation of nucleosomal histones by p300 facilitates transcription from tax-responsive human T-cell leukemia virus type 1 chromatin templateHanxin Lu, Cynthia A Pise-Masison, Terace M Fletcher, et al.
Immunity & Ageing : I & A|April 18, 2017
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adultsLouis Fries, Vivek Shinde, Jeffrey J Stoddard, et al.
Vaccine|June 6, 2017
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing ageAllison August, Gregory M Glenn, Eloi Kpamegan, et al.
The Journal of Infectious Diseases|August 12, 2015
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing AgeGregory M Glenn, Louis F Fries, D Nigel Thomas, et al.
Vaccine|August 17, 2019
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protectionNita Patel, Mike J Massare, Jing-Hui Tian, et al.
Vaccine|November 17, 2012
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccineGregory M Glenn, Gale Smith, Louis Fries, et al.
Pageof 3